Related references
Note: Only part of the references are listed.Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis
Doran Ksienski et al.
CLINICAL LUNG CANCER (2019)
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
Deborah B. Doroshow et al.
CLINICAL CANCER RESEARCH (2019)
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
Alessio Cortellini et al.
CLINICAL LUNG CANCER (2019)
Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors
Suthee Rapisuwon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
V. Ellen Maher et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence
Antonio Passaro et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Fiamma Berner et al.
JAMA ONCOLOGY (2019)
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
Audrey Simonaggio et al.
JAMA ONCOLOGY (2019)
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
Biagio Ricciuti et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma
Alice Indini et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
E. E. Vokes et al.
ANNALS OF ONCOLOGY (2018)
Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab
Wungki Park et al.
CLINICAL LUNG CANCER (2018)
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Rituparna Das et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Inpatient admissions related to immune-related adverse effects (irAE) among patients treated with immune checkpoint inhibitors for advanced malignancy: A tsunami is coming, but are we ready?
Kerry Lynn Reynolds et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Fernando C. Santini et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer
Koji Haratani et al.
JAMA ONCOLOGY (2018)
Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer
Dwight H. Owen et al.
CLINICAL LUNG CANCER (2018)
A multidisciplinary toxicity team for cancer immunotherapy-related adverse events
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
Karthik Suresh et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Immune Checkpoint Inhibitor Toxicity in 2018
Douglas B. Johnson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy
Arabella Young et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immune-Related Adverse Events and Their Effect on Outcomes in Patients (pts) with Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab
Shawn Kothari et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Drug-Related Pneumonitis in the Era of Precision Cancer Therapy
Mizuki Nishino et al.
JCO PRECISION ONCOLOGY (2017)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Share Paper
